Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 2
2001 1
2003 1
2005 1
2006 3
2007 1
2008 1
2009 3
2010 1
2011 4
2012 2
2013 2
2014 5
2015 8
2016 2
2017 6
2018 3
2019 3
2020 2
2021 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausová J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry D, McKendrick J, Polikoff J, Tellier A, Castan R, Allegra C. Van Cutsem E, et al. Among authors: prausova j. J Clin Oncol. 2012 Oct 1;30(28):3499-506. doi: 10.1200/JCO.2012.42.8201. Epub 2012 Sep 4. J Clin Oncol. 2012. PMID: 22949147 Clinical Trial.
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.
Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, Prausová J, Garcia-Alfonso P, Yamazaki K, Clingan PR, Lonardi S, Kim TW, Simms L, Chang SC, Nasroulah F; RAISE Study Investigators. Tabernero J, et al. Among authors: prausova j. Lancet Oncol. 2015 May;16(5):499-508. doi: 10.1016/S1470-2045(15)70127-0. Epub 2015 Apr 12. Lancet Oncol. 2015. PMID: 25877855 Clinical Trial.
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H. Henry DH, et al. Among authors: prausova j. J Clin Oncol. 2011 Mar 20;29(9):1125-32. doi: 10.1200/JCO.2010.31.3304. Epub 2011 Feb 22. J Clin Oncol. 2011. PMID: 21343556 Clinical Trial.
Ultrahypofractionated Proton Radiation Therapy in the Treatment of Low and Intermediate-Risk Prostate Cancer-5-Year Outcomes.
Kubeš J, Haas A, Vondráček V, Andrlík M, Navrátil M, Sláviková S, Vítek P, Dědečková K, Prausová J, Ondrová B, Vinakurau Š, Grebenyuk A, Doležal T, Velacková B, Rosina J. Kubeš J, et al. Among authors: prausova j. Int J Radiat Oncol Biol Phys. 2021 Jul 15;110(4):1090-1097. doi: 10.1016/j.ijrobp.2021.02.014. Epub 2021 Feb 12. Int J Radiat Oncol Biol Phys. 2021. PMID: 33587990
Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry.
Kopeckova K, Buchler T, Bortlicek Z, Hejduk K, Chloupkova R, Melichar B, Pokorna P, Tomasek J, Linke Z, Petruzelka L, Kiss I, Prausova J. Kopeckova K, et al. Among authors: prausova j. Target Oncol. 2017 Feb;12(1):89-95. doi: 10.1007/s11523-016-0458-1. Target Oncol. 2017. PMID: 27638381
Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients.
Novakova-Jiresova A, Kopeckova K, Boublikova L, Chloupkova R, Melichar B, Petruzelka L, Finek J, Fiala O, Grell P, Batko S, Linke Z, Kiss I, Prausova J, Buchler T. Novakova-Jiresova A, et al. Among authors: prausova j. Cancer Manag Res. 2020 Jul 3;12:5365-5372. doi: 10.2147/CMAR.S255332. eCollection 2020. Cancer Manag Res. 2020. PMID: 32753954 Free PMC article.
Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study.
Yoshino T, Portnoy DC, Obermannová R, Bodoky G, Prausová J, Garcia-Carbonero R, Ciuleanu T, García-Alfonso P, Cohn AL, Van Cutsem E, Yamazaki K, Lonardi S, Muro K, Kim TW, Yamaguchi K, Grothey A, O'Connor J, Taieb J, Wijayawardana SR, Hozak RR, Nasroulah F, Tabernero J. Yoshino T, et al. Among authors: prausova j. Ann Oncol. 2019 Jan 1;30(1):124-131. doi: 10.1093/annonc/mdy461. Ann Oncol. 2019. PMID: 30339194 Free PMC article. Clinical Trial.
Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study.
Tabernero J, Hozak RR, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Prausová J, Muro K, Siegel RW, Konrad RJ, Ouyang H, Melemed SA, Ferry D, Nasroulah F, Van Cutsem E. Tabernero J, et al. Among authors: prausova j. Ann Oncol. 2018 Mar 1;29(3):602-609. doi: 10.1093/annonc/mdx767. Ann Oncol. 2018. PMID: 29228087 Free PMC article. Clinical Trial.
46 results